KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Other Operating Expenses (2016 - 2025)

AbbVie (ABBV) has disclosed Other Operating Expenses for 14 consecutive years, with $217.0 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 3000.0% to $217.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 billion through Dec 2025, up 64057.14% year-over-year, with the annual reading at $241.0 million for FY2025, 3342.86% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $217.0 million at AbbVie, up from $24.0 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $4.4 billion in Q1 2021, with the low at -$229.0 million in Q3 2022.
  • Average Other Operating Expenses over 5 years is $798.9 million, with a median of $118.5 million recorded in 2021.
  • The sharpest move saw Other Operating Expenses plummeted 145.8% in 2022, then surged 3000.0% in 2025.
  • Over 5 years, Other Operating Expenses stood at $500.0 million in 2021, then tumbled by 99.8% to $1.0 million in 2022, then soared by 16800.0% to $169.0 million in 2023, then tumbled by 95.86% to $7.0 million in 2024, then soared by 3000.0% to $217.0 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $217.0 million, $24.0 million, and $4.2 billion for Q4 2025, Q2 2025, and Q1 2025 respectively.